Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Salivary Gland Cancer

 

Eribulin for Locally Advanced Salivary Gland Cancers (7674)
Phase II Trial of Eribulin for Locally Advanced Refractory or Metastatic Salivary Gland Cancers

Investigator: Keith D. Eaton, MD;   Conditions: Salivary Gland Cancer;    Status: Recruiting;   Study ID: NCT01613768